01—Abstract
Summary
Summary of the 10-K filed August 13, 2012. Cited figures are marked; the original filing is the authoritative source.
This 10-K filing for Techs Loanstar, Inc. (which subsequently changed its name to Quture International, Inc.) for the fiscal year ended April 30, 2012, marks a significant transition for the company.
In August 2011, Techs Loanstar completed a share exchange transaction, effectively acquiring Quture, Inc. and adopting its business plan focused on developing medical software with tools and analytics to reduce healthcare costs and improve clinical performance. Consequently, the financial statements presented are primarily those of Quture, Inc. from the acquisition date forward. The company generated minimal revenue of $40,900a for the fiscal year, incurring a substantial net loss of $2,676,257.
This indicates that the company is in its early stages of development and commercialization, with significant ongoing expenses related to software development and general operations. The company faces substantial risks, including a limited operating history, a need for additional financing to continue operations, and uncertainty regarding market acceptance of its innovative products.
02—Key points
Key Highlights
- Company underwent a significant name change to Quture International, Inc. and a share exchange transaction with Quture, Inc. in August 2011, with Quture's business plan adopted.
- The company reported minimal revenue of $40,900 for the fiscal year ended April 30, 2012, a significant increase from $19,900 in the prior year.
- A substantial net loss of $2,676,257 was incurred for the fiscal year, compared to a loss of $119,269 in the prior year, reflecting significant investment in development and operations.
- The company has a limited operating history and is classified as a 'smaller reporting company', indicating its early stage of development.
- Significant risk factors are highlighted, including the need for additional financing, uncertainty of market acceptance for new products, and potential competition.
- The company is heavily reliant on key technology partnerships, particularly with InterSystems Corporation, for its product development and strategy.
- Auditor's report expresses substantial doubt about the company's ability to continue as an ongoing concern, contingent on successful fundraising and commercialization.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2012filed August 13, 2012Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $21K$41K | −48.7% |
| Operating Expenses | $2.33M$139K | +1571.4% |
| Operating Income | $7.55M-$119K | +6431.9% |
| Interest Expense | -$169K-$62K | −173.9% |
| Net Income | -$2.68M-$119K | −2143.9% |
| EPS (Basic) | $-0.01$-0.01 | 0.0% |
05—Questions
Frequently Asked Questions
What is the primary business of Techs Loanstar, Inc. (now Quture International, Inc.)?
Techs Loanstar, Inc., which changed its name to Quture International, Inc., is focused on developing medical software solutions and analytics designed to reduce healthcare costs and improve clinical performance and patient outcomes. Their primary products are QualOptima (for clinical performance measurement) and QSurg (an EMR for surgery centers).
What was the financial performance for the fiscal year ended April 30, 2012?
The company reported very low revenue of $40,900 for the fiscal year. However, it incurred a significant net loss of $2,676,257, indicating substantial investment in product development and operations, and a lack of substantial revenue generation to cover expenses at this stage.
What are the major risks identified in the filing?
Key risks include the company's limited operating history, its significant need for additional financing to continue operations and execute its business plan, uncertainty surrounding market acceptance of its innovative healthcare software products, and the potential for intense competition from established players in the healthcare IT market. The auditor's report also raises substantial doubt about the company's ability to continue as a going concern.
What is the company's strategy for growth and revenue generation?
The company's strategy involves developing and commercializing its QualOptima and QSurg products, targeting hospitals and physician groups. They plan to leverage key partnerships, such as with InterSystems, and capitalize on healthcare reform initiatives like the Affordable Care Act to drive adoption. The company also anticipates accelerating growth through potential mergers and acquisitions.
06—Continue